Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trialSalvatore Siena, Takayuki Yoshino, Fotios Loupakis et al.|The Lancet Oncology|2021Cited by 411
Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalitionBob T. Li, Yi‐Long Wu, Bobby Daly et al.|Nature Medicine|2022Cited by 52